HDFN
MCID: HML054
MIFTS: 22

Hemolytic Disease Due to Fetomaternal Alloimmunization (HDFN)

Categories: Blood diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Hemolytic Disease Due to Fetomaternal Alloimmunization

MalaCards integrated aliases for Hemolytic Disease Due to Fetomaternal Alloimmunization:

Name: Hemolytic Disease Due to Fetomaternal Alloimmunization 58
Hemolytic Disease of the Fetus and Newborn 58
Hdfn 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 32 P55 P55.9
ICD10 via Orphanet 33 P55.0 P55.1 P55.8 more
Orphanet 58 ORPHA275938

Summaries for Hemolytic Disease Due to Fetomaternal Alloimmunization

MalaCards based summary : Hemolytic Disease Due to Fetomaternal Alloimmunization, also known as hemolytic disease of the fetus and newborn, is related to retinohepatoendocrinologic syndrome and blood group, gerbich system. An important gene associated with Hemolytic Disease Due to Fetomaternal Alloimmunization is SLC29A1 (Solute Carrier Family 29 Member 1 (Augustine Blood Group)). The drugs Darbepoetin alfa and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include testes, breast and monocytes.

Related Diseases for Hemolytic Disease Due to Fetomaternal Alloimmunization

Diseases related to Hemolytic Disease Due to Fetomaternal Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 20, show less)
# Related Disease Score Top Affiliating Genes
1 retinohepatoendocrinologic syndrome 11.6
2 blood group, gerbich system 11.4
3 fetal erythroblastosis 11.3
4 hydrops fetalis, nonimmune 10.4
5 bilirubin metabolic disorder 10.2
6 posttransplant acute limbic encephalitis 10.2
7 kernicterus 10.1
8 blood group--kell system 10.0
9 yemenite deaf-blind hypopigmentation syndrome 10.0
10 branchiootic syndrome 1 10.0
11 blood group, junior system 10.0
12 deficiency anemia 10.0
13 exanthem 10.0
14 respiratory failure 10.0
15 opioid abuse 10.0
16 thrombocytopenia 10.0
17 cerebral palsy 10.0
18 purpura 10.0
19 hemolytic anemia 10.0
20 hypoglycemia 10.0

Graphical network of the top 20 diseases related to Hemolytic Disease Due to Fetomaternal Alloimmunization:



Diseases related to Hemolytic Disease Due to Fetomaternal Alloimmunization

Symptoms & Phenotypes for Hemolytic Disease Due to Fetomaternal Alloimmunization

Drugs & Therapeutics for Hemolytic Disease Due to Fetomaternal Alloimmunization

Drugs for Hemolytic Disease Due to Fetomaternal Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 4, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
2 Hematinics Phase 2, Phase 3
3 Immunoglobulins Phase 2
4 Antibodies Phase 2

Interventional clinical trials:

(showing 4, show less)
# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial on the Use of EPO to Reduce Top-up Transfusions in Neonates With Red Blood Cell Alloimmunization Treated With Intrauterine Transfusions Recruiting NCT03104426 Phase 2, Phase 3 Darbepoetin Alfa
2 A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Recruiting NCT03842189 Phase 2 M281
3 Clinical Professor of Shanghai Tongji Hospital Approved for marketing NCT02969174
4 A Multicenter, Prospective Observational Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn Recruiting NCT03755128

Search NIH Clinical Center for Hemolytic Disease Due to Fetomaternal Alloimmunization

Genetic Tests for Hemolytic Disease Due to Fetomaternal Alloimmunization

Anatomical Context for Hemolytic Disease Due to Fetomaternal Alloimmunization

MalaCards organs/tissues related to Hemolytic Disease Due to Fetomaternal Alloimmunization:

40
Testes, Breast, Monocytes, Kidney, B Cells

Publications for Hemolytic Disease Due to Fetomaternal Alloimmunization

Articles related to Hemolytic Disease Due to Fetomaternal Alloimmunization:

(showing 241, show less)
# Title Authors PMID Year
1
Diagnostic value of laboratory monitoring to predict severe hemolytic disease of the fetus and newborn in non-D and non-K-alloimmunized pregnancies. 61
31867744 2020
2
Suppression of compensatory erythropoiesis in hemolytic disease of the fetus and newborn due to intrauterine transfusions. 61
31978433 2020
3
IgG3 anti-Kell allotypic variation results in differential antigen binding and phagocytosis. 61
31930726 2020
4
Rhesus D alloimmunization in pregnancy from 1996 to 2015 in Iceland: a nation-wide population study prior to routine antenatal anti-D prophylaxis. 61
31850521 2020
5
Impact of intrauterine transfusion on fetal coagulation physiology by thromboelastography. 61
31994748 2020
6
Cold reacting anti-M causing delayed hemolytic disease of the newborn. 61
31670408 2019
7
Clinical approach after identification of a rare anti-Ena in a prenatal sample. 61
31935334 2019
8
The use of IVIg in fetal and neonatal alloimmune thrombocytopenia- Principles and mechanisms. 61
31926738 2019
9
Acute hemolytic transfusion reaction associated with anti-Mta : case report and review of the literature. 61
31503331 2019
10
Coordinating Care Across the Perinatal Continuum in Hemolytic Disease of the Fetus and Newborn: The Timely Handoff of a Positive Maternal Anti-Erythrocyte Antibody Screen. 61
31451186 2019
11
The prenatal intervention of pregnancy complicated with anti-Kell isoimmunization: a review. 61
31571493 2019
12
Blood Donation During Pregnancy Due to Anti-Ku Hemolytic Disease of the Fetus and Newborn. 61
31089725 2019
13
Amplicon Sequencing-Based Noninvasive Fetal Genotyping for RHD-Positive D Antigen-Negative Alleles. 61
31488553 2019
14
Conservative Management of Hyperferritinemia in Hemolytic Disease of the Fetus and Newborn: A Case Report and Review of the Literature. 61
31460887 2019
15
Fatal hemolytic disease of the fetus and newborn caused by anti-Jra antibody: A case report and literature review. 61
31324575 2019
16
A case of mild HDFN caused by anti-C, anti-D, and anti-G: Diagnostic strategy and clinical significance of distinguishing anti-G from anti-D and anti-C. 61
31303507 2019
17
Anemic Disease of the Newborn With Little Increase in Hemolysis and Erythropoiesis Due to Maternal Anti-Jra: A Case Study and Review of the Literature. 61
31227265 2019
18
Heat elution: a modification of the Landsteiner-Miller method. 61
31246486 2019
19
Prevention of hemolytic transfusion reactions with intravenous immunoglobulin prophylaxis in U- patients with anti-U. 61
30861151 2019
20
Transfusion-related red blood cell alloantibodies: induction and consequences. 61
30808636 2019
21
Molecular Detection of Glycophorins A and B Variant Phenotypes and their Clinical Relevance. 61
30910255 2019
22
Identification of red blood cell antibodies in maternal breast milk implicated in prolonged hemolytic disease of the fetus and newborn. 61
30720868 2019
23
Severe Fetal Hemolysis and Cholestasis Due to High-Titer Maternal IgG Anti-A Antibodies. 61
30872329 2019
24
Postponing early intrauterine transfusion with intravenous immunoglobulin treatment: the PETIT study on severe hemolytic disease of the fetus and newborn. 61
30837065 2019
25
Hemolytic disease of the fetus and newborn due to alloanti-M: three Chinese case reports and a review of the literature. 61
30520533 2019
26
Prevalence and specificity of clinically significant red cell alloantibodies in pregnant women - a study from a tertiary care hospital in Southeast Michigan. 61
31692490 2019
27
Bombay phenotype (Oh ) and high-titer anti-H in pregnancy: two case reports and a review of the literature. 61
30260479 2018
28
Sulfhydryl treatment of serum or plasma for the reduction of IgM antibodies. 61
30624946 2018
29
The first case of severe acute hemolytic transfusion reaction caused by anti-Sc2. 61
30299537 2018
30
Neonatal Alloimmune Neutropenia. 61
31049048 2018
31
Severe hemolytic disease of the fetus and newborn due to allo-anti-D in a patient with a partial DEL phenotype arising from the variant allele described as RHD*148+1T (RHD*01EL.31). 61
30222865 2018
32
Red Blood Cell Alloimmunization in the Pregnant Patient. 61
30097223 2018
33
Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. 61
30063902 2018
34
Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. 61
29902448 2018
35
Clinical significance of antibodies to antigens in the Raph, John Milton Hagen, I, Globoside, Gill, Rh-associated glycoprotein, FORS, JR, LAN, Vel, CD59, and Augustine blood group systems. 61
30295501 2018
36
Clinical significance of antibodies to antigens in the Scianna, Dombrock, Colton, Landsteiner-Weiner, Chido/Rodgers, H, Kx, Cromer, Gerbich, Knops, Indian, and Ok blood group systems. 61
30295505 2018
37
Determination of fetal RHD type in plasma of RhD negative pregnant women. 61
29869532 2018
38
Predicted S and s phenotypes from genotyping results among Thai populations to prevent transfusion-induced alloimmunization risks. 61
30078741 2018
39
Frequency of Red Cell Alloantibodies in Pregnant Females of Navsari District: An Experience that Favours Inclusion of Screening for Irregular Erythrocyte Antibody in Routine Antenatal Testing Profile. 61
30065546 2018
40
ABO incompatibility and RhIG immunoprophylaxis protect against non-D alloimmunization by pregnancy. 61
29624682 2018
41
Transfusions of least-incompatible blood with intravenous immunoglobulin plus steroids cover in two patients with rare antibody. 61
29732576 2018
42
Clinical significance of antibodies to antigens in the International Society of Blood Transfusion collections, 700 series of low-incidence antigens, and 901 series of high-incidence antigens. 61
29989417 2018
43
Molecular characterization and multidisciplinary management of Gerbich hemolytic disease of the newborn. 61
29469208 2018
44
Molecular basis of weak D expression in the Indian population and report of a novel, predominant variant RHD allele. 61
29479713 2018
45
Evaluation of a Decision Tree for Efficient Antenatal Red Blood Cell Antibody Screening. 61
29337843 2018
46
Lessons learned from the implementation of non-invasive fetal RHD screening. 61
29616835 2018
47
A unique major histocompatibility complex Class II-binding register correlates with HLA-DR11-associated immunogenicity of the major K blood group antigen. 61
29464723 2018
48
A proposed new low-frequency antigen in the Augustine blood group system associated with a severe case of hemolytic disease of the fetus and newborn. 61
29504136 2018
49
ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program. 61
29410540 2018
50
Jk3 alloantibodies during pregnancy-blood bank management and hemolytic disease of the fetus and newborn risk. 61
29479723 2018
51
Red blood cells, still vital after all these years: Commentary on Canadian Blood Services' International Symposium 2017. 61
29691151 2018
52
Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion. 61
29250791 2018
53
How shall we transfuse Hippolyta? 61
29097176 2018
54
Erythrocyte Saturation with IgG Is Required for Inducing Antibody-Mediated Immune Suppression and Impacts Both Erythrocyte Clearance and Antigen-Modulation Mechanisms. 61
29358275 2018
55
Management of pregnancy sensitized with anti-Inb with monocyte monolayer assay and maternal blood donation. 61
29608321 2018
56
A new biosensor for noninvasive determination of fetal RHD status in maternal blood of RhD negative pregnant women. 61
29874251 2018
57
The development of D antibodies after D-mismatched kidney transplantation in a setting of reduced immunosuppression. 61
29193117 2018
58
Rhesus blood group haplotype frequencies among blood donors in southwestern Uganda. 61
29950915 2018
59
A brief overview of clinical significance of blood group antibodies. 61
29608320 2018
60
Anti-Vel alloimmunization and severe hemolytic disease of the fetus and newborn. 61
29378146 2017
61
Prevention of hemolytic disease of the fetus and newborn: what have we learned from animal models? 61
28719385 2017
62
Persistence of Villous Immaturity in Term Deliveries Following Intrauterine Transfusion for Parvovirus B19 Infection and RhD-associated Hemolytic Disease of the Fetus and Newborn. 61
29187036 2017
63
D antibodies in pregnant women in multiethnic Suriname: the observational RheSuN study. 61
28703855 2017
64
A LU:-16 individual with antibodies. 61
29043828 2017
65
A Guide to Terminology for Rh Immunoprophylaxis. 61
28796682 2017
66
Persistent hemolytic disease of the fetus and newborn (HDFN) associated with passive acquisition of anti-D in maternal breast milk. 61
28580721 2017
67
Postpartum acute hemolytic transfusion reactions associated with anti-Lea in two pregnancies complicated by preeclampsia. 61
29043829 2017
68
Usefulness of maternal red cell antibodies to predict hemolytic disease of the fetus and newborn and significant neonatal hyperbilirubinemia: a retrospective study. 61
28076300 2017
69
Anti-D in a mother, hemizygous for the variant RHD*DNB gene, associated with hemolytic disease of the fetus and newborn. 61
28639307 2017
70
Rapid RHD Zygosity Determination Using Digital PCR. 61
28615230 2017
71
Neonatal management and outcome in alloimmune hemolytic disease. 61
28503958 2017
72
The Kidd (JK) Blood Group System. 61
28065763 2017
73
The Vel blood group system: a review. 61
28657763 2017
74
Two cases of the variant RHD*DAU5 allele associated with maternal alloanti-D. 61
28657764 2017
75
What is it really? Anti-G or Anti-D plus Anti-C: Clinical Significance in Antenatal Mothers. 61
28596661 2017
76
Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn - review on current management and outcome. 61
28277805 2017
77
Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study. 61
28164304 2017
78
A Jordanian family with three sisters apparently homozygous for Mk and evidence for clinical significance of antibodies produced by Mk Mk individuals. 61
27807866 2017
79
Anti-G with concomitant anti-C and anti-D: A case report in a pregnant woman. 61
28316444 2017
80
Anti-K1 (Kell) Antibody Expressed in Maternal Breastmilk: A Case Report of a Neonate with Multiple Intrauterine Transfusions and Postnatal Exposure to Kell Antibody in Maternal Breastmilk. 61
28357148 2017
81
Clinical Significance of an Alloantibody against the Kell Blood Group Glycoprotein. 61
28275334 2017
82
Anti-D Antibodies in Pregnant D Variant Antigen Carriers Initially Typed as RhD. 61
27994529 2016
83
Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations. 61
27397673 2016
84
The Augustine blood group system, 48 years in the making. 61
27834482 2016
85
Antibody-mediated immune suppression is improved when blends of anti-RBC monoclonal antibodies are used in mice. 61
27330002 2016
86
[Positive Coomb's test in newborns; causes and clinical consequences Summary of cases diagnosed in the Blood Bank in the years 2005 to 2012]. 61
27531851 2016
87
[Hemolytic Disease of the Fetus and Newborn, where are we now?[Editorial]]. 61
27531850 2016
88
Identification of new KLF1 and LU alleles during the resolution of Lutheran typing discrepancies. 61
27043150 2016
89
Unexpected red blood cell antibody distributions in Chinese people by a systematic literature review. 61
26638180 2016
90
Fetal RHD Genotyping Using Real-Time Polymerase Chain Reaction Analysis of Cell-Free Fetal DNA in Pregnancy of RhD Negative Women in South of Iran. 61
27123202 2016
91
Hemolytic Disease of the Fetus and Newborn due to Intravenous Drug Use. 61
26989567 2016
92
Hemolytic disease of the fetus and newborn in the molecular era. 61
26589360 2016
93
RhD negativity among pregnant women in multiethnic Suriname. 61
26677093 2016
94
Red Cell Alloimmunization to Rhesus Antigen Among Pregnant Women Attending a Tertiary Care Hospital in Oman. 61
26813962 2016
95
Distribution of DI*A and DI*B Allele Frequencies and Comparisons among Central Thai and Other Populations. 61
27764238 2016
96
Immunoglobulins in Neonates with Rhesus Hemolytic Disease of the Fetus and Newborn: Long-Term Outcome in a Randomized Trial. 61
26159803 2016
97
Anti-Di(b) causing hemolytic disease of the fetus and newborn and the challenges of anti-Di(b) in perinatal management in China. 61
26578228 2015
98
Prevalence and Specificity of Red Blood Cell Alloantibodies in Patients from China During 1994-2013. 61
26708902 2015
99
Duffy blood group genotyping in Thai blood donors. 61
26354350 2015
100
Non-invasive fetal ABO genotyping in maternal plasma using real-time PCR. 61
26068903 2015
101
Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing. 61
26511760 2015
102
Alloimmune Red Blood Cell Antibodies: Prevalence and Pathogenicity in a Canadian Prenatal Population. 61
26605447 2015
103
Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. 61
25808011 2015
104
Anti-G antibody in alloimmunized pregnant women: Report of two cases. 61
26420948 2015
105
Hemolytic disease of the fetus and newborn due to multiple maternal antibodies. 61
25644438 2015
106
SARA: a "new" low-frequency MNS antigen (MNS47) provides further evidence of the extreme diversity of the MNS blood group system. 61
25523184 2015
107
The prevalence of anti-K in Canadian prenatal patients. 61
25968929 2015
108
Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. 61
25603954 2015
109
Management of a pregnant woman with anti-holley alloantibody. 61
26019709 2015
110
Provision of KEL1-negative blood to obstetric patients: a 3-year single-institution retrospective review. 61
25118004 2015
111
Rh(O)D immune globulin products for prevention of alloimmunization during pregnancy. 61
25631833 2015
112
High-resolution melting analysis for genotyping Duffy blood group antigens. 61
26024627 2015
113
Occurrence of anti-D alloantibodies among pregnant women in Kasese District, Western Uganda. 61
25945071 2015
114
Maternal anti-M induced hemolytic disease of newborn followed by prolonged anemia in newborn twins. 61
25722586 2015
115
Review of fetal and neonatal immune cytopenias. 61
25679972 2015
116
Kell and Kx blood group systems. 61
26308465 2015
117
Development and Detection of Kidd Antibodies. 61
26199265 2015
118
Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. 61
26637714 2015
119
Case report: Severe hemolytic disease of the fetus and newborn due to anti-C+G. 61
26829179 2015
120
Suspected acute hemolytic transfusion reaction mediated by anti-Di(a). 61
27187197 2015
121
Responder individuality in red blood cell alloimmunization. 61
25670932 2014
122
Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care. 61
24431264 2014
123
Hemolytic disease of the fetus and newborn caused by anti-Lan. 61
24188628 2014
124
Noninvasive fetal RhD genotyping. 61
24642067 2014
125
Anti-D alloimmunization after D-incompatible platelet transfusions: a 14-year single-institution retrospective review. 61
23829356 2014
126
Alleles of the LAN blood group system: molecular and serologic investigations. 61
23763549 2014
127
Anti-KANNO: a novel alloantibody against a red cell antigen of high frequency. 61
24485899 2014
128
RhD Specific Antibodies Are Not Detectable in HLA-DRB1(*)1501 Mice Challenged with Human RhD Positive Erythrocytes. 61
25628657 2014
129
Successful management of neonatal alloimmune thrombocytopenia in the second pregnancy: a case report. 61
24728253 2014
130
Hemolytic disease of the fetus and newborn with late-onset anemia due to anti-M: a case report and review of the Japanese literature. 61
24262303 2014
131
Antibody-mediated glycophorin C coligation on K562 cells induces phosphatidylserine exposure and cell death in an atypical apoptotic process. 61
23278312 2013
132
Hemolytic disease of the fetus and newborn. 61
24518377 2013
133
Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies. 61
23750781 2013
134
A mouse model of hemolytic disease of the newborn. 61
23970354 2013
135
Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model. 61
23801629 2013
136
Postnatal outcome in neonates with severe Rhesus c compared to rhesus D hemolytic disease. 61
23113703 2013
137
The risk assessment study for hemolytic disease of the fetus and newborn in a University Hospital in Turkey. 61
23619329 2013
138
Reliable Determination of Fetal RhD Status by RHD Genotyping from Maternal Plasma. 61
23637648 2013
139
P1PK: the blood group system that changed its name and expanded. 61
24046920 2013
140
The LAN blood group system:a review. 61
24689682 2013
141
Comparison of different blood sample processing methods for sensitive detection of low level chimerism by RHD real-time PCR assay. 61
23511951 2013
142
Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility. 61
24689681 2013
143
Hemolytic disease of the fetus and newborn owing to anti-U, successfully treated with repeated intrauterine transfusions. 61
24094236 2013
144
An AQP1 allele associated with co(a-b-) phenotype. 61
24046915 2013
145
A review of the JR blood group system. 61
24094238 2013
146
An easy and efficient strategy for KEL genotyping in a multiethnic population. 61
23741186 2013
147
The Diego blood group system: a review. 61
24094240 2013
148
Hemolytic disease of the fetus and newborn caused by anti-E. 61
23559775 2013
149
Neonatal morbidity after exchange transfusion for red cell alloimmune hemolytic disease. 61
23235106 2013
150
Biphasic clearance of incompatible red blood cells through a novel mechanism requiring neither complement nor Fcγ receptors in a murine model. 61
22502635 2012
151
Solving the dilemma of prevention of red cell alloimmunization. 61
23046234 2012
152
Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. 61
22251227 2012
153
Hemolytic disease of the fetus and newborn caused by anti-D and anti-S alloantibodies: a case report. 61
22348809 2012
154
Blood group genotyping in a multitrauma patient: a case report. 61
23286553 2012
155
Hemolytic disease of the fetus and newborn caused by an antibody to a low-prevalence antigen, anti-SARA. 61
21414007 2011
156
Diagnostic laboratory technologies for the fetus and neonate with isoimmunization. 61
21641488 2011
157
Blueberry muffin rash, hyperbilirubinemia, and hypoglycemia: a case of hemolytic disease of the fetus and newborn due to anti-Kp(a). 61
21525882 2011
158
Transfusion medicine and the pregnant patient. 61
21444037 2011
159
Unexpected suppression of anti-Fya and prevention of hemolytic disease of the fetus and newborn after administration of Rh immune globulin. 61
20946183 2011
160
Sixty years of antibodies to MNS system hybrid glycophorins: what have we learned? 61
21345645 2011
161
[The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn]. 61
21568074 2011
162
Hemolytic disease of the fetus and newborn: Current trends and perspectives. 61
21572705 2011
163
Possible suppression of fetal erythropoiesis by the Kell blood group antibody anti-Kp(a). 61
22356520 2011
164
Frequencies of maternal red blood cell alloantibodies in Port Harcourt, Nigeria. 61
21572714 2011
165
Serologic and molecular characterization of D variants in Brazilians: impact for typing and transfusion strategy. 61
22356480 2011
166
Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. 61
21154165 2010
167
Rh isoimmunization in Sub-Saharan Africa indicates need for universal access to anti-RhD immunoglobulin and effective management of D-negative pregnancies. 61
21270966 2010
168
Molecular determination of RHD zygosity: predicting risk of hemolytic disease of the fetus and newborn related to anti-D. 61
21072752 2010
169
Successful use of maternal blood in the management of severe hemolytic disease of the fetus and newborn due to anti-Kp(b). 61
20951648 2010
170
Red blood cell alloimmunization from an African perspective. 61
20827185 2010
171
ABO hemolytic disease of the fetus and newborn: an iatrogenic complication of heterologous assisted reproductive technology-induced pregnancy. 61
20492611 2010
172
Anti-glycophorin C induces mitochondrial membrane depolarization and a loss of extracellular regulated kinase 1/2 protein kinase activity that is prevented by pretreatment with cytochalasin D: implications for hemolytic disease of the fetus and newborn caused by anti-Ge3. 61
20456692 2010
173
Non-invasive fetal RHD genotyping in the first trimester of pregnancy. 61
20482298 2010
174
The relationship between blood groups and disease. 61
20308598 2010
175
Noninvasive fetal blood grouping: present and future. 61
20513561 2010
176
Absence of hemolytic disease of fetus and newborn despite maternal high-titer IgG anti-Ku. 61
21214298 2010
177
Prevention of Rh sensitization in the context of trauma: two case reports. 61
20027640 2010
178
The Gerbich blood group system: a review. 61
20932076 2010
179
The Duffy blood group system: a review. 61
20932074 2010
180
Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models? 61
19730101 2009
181
A curious case of anti-D antibody titer. 61
19879523 2009
182
Noninvasive approach for the management of hemolytic disease of the fetus. 61
21083022 2009
183
Red cell genotyping and the future of pretransfusion testing. 61
19411635 2009
184
A novel KEL*1,3 allele with weak Kell antigen expression confirming the cis-modifier effect of KEL3. 61
19347978 2009
185
Cell-free fetal DNA in the maternal serum and plasma: current and evolving applications. 61
19262379 2009
186
Fatal hemolytic disease of the fetus and newborn possibly due to anti-Jr. 61
19335378 2009
187
The JAL antigen (RH48) is the result of a change in RHCE that encodes Arg114Trp. 61
19170983 2009
188
Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. 61
19085963 2009
189
Anti-Kpa-induced severe delayed hemolytic transfusion reaction. 61
19927619 2009
190
MNS blood group system: a review. 61
20406014 2009
191
Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. 61
20008198 2009
192
The use of maternal plasma for prenatal RhD blood group genotyping. 61
18839110 2009
193
Lutheran. 61
20406022 2009
194
Women's attitude towards prenatal screening for red blood cell antibodies, other than RhD. 61
19014424 2008
195
Alexander S. Wiener: the man and his work. 61
18848157 2008
196
Hemolytic disease of the fetus and newborn due to anti-Ge3: combined antibody-dependent hemolysis and erythroid precursor cell growth inhibition. 61
18720327 2008
197
Fatal hemolytic disease of the fetus and newborn associated with anti-Jr. 61
18522708 2008
198
One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. 61
18507749 2008
199
Transfusion of IgG-opsonized foreign red blood cells mediates reduction of antigen-specific B cell priming in a murine model. 61
18606646 2008
200
Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. 61
18248570 2008
201
An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients. 61
18330822 2008
202
Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services. 61
18353252 2008
203
Noninvasive genotyping fetal Kell blood group (KEL1) using cell-free fetal DNA in maternal plasma by MALDI-TOF mass spectrometry. 61
18241084 2008
204
The potential of blood group genotyping for transfusion medicine practice. 61
19856724 2008
205
In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn. 61
17764508 2008
206
Anti-e found in a case of hemolytic disease of the fetus and newborn make use of the IGHV3 superspecies genes. 61
18184235 2008
207
Noninvasive approaches to the management of RhD hemolytic disease of the fetus and newborn. 61
18184231 2008
208
Predictive blood group genetics in hemolytic disease of the fetus and newborn: a 10-year review of a laboratory evaluation of amniotic fluid-derived DNA. 61
17705237 2007
209
Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. 61
17958542 2007
210
Management of pregnancies complicated by anti-Fy(a) alloimmunization. 61
17880612 2007
211
Blood product replacement in the perinatal period. 61
17825684 2007
212
Fetal blood group genotyping. 61
17593289 2007
213
Quantitation of RHD by real-time polymerase chain reaction for determination of RHD zygosity and RHD mosaicism/chimerism: an evaluation of four quantitative methods. 61
17381631 2007
214
Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D. 61
17302778 2007
215
Blood group antibodies and their significance in transfusion medicine. 61
17174221 2007
216
A KEL gene encoding serine at position 193 of the Kell glycoprotein results in expression of KEL1 antigen. 61
17076841 2006
217
Anti-D in Rh positive pregnancies. 61
17000249 2006
218
Fetal blood group genotyping: present and future. 61
17108196 2006
219
In vitro functional test of two subclasses of an anti-RhD antibody produced by transient expression in COS cells. 61
16725010 2006
220
Update on HDFN: new information on long-standing controversies. 61
17430078 2006
221
Noninvasive prenatal RHD genotyping by real-time polymerase chain reaction using plasma from D-negative pregnant women. 61
16325598 2005
222
Twin pregnancy complicated by severe hemolytic disease of the fetus and newborn due to anti-g and anti-C. 61
16260562 2005
223
Antenatal maternal administration of phenobarbital for the prevention of exchange transfusion in neonates with hemolytic disease of the fetus and newborn. 61
15695990 2005
224
RHD maternal-fetal genotype incompatibility and schizophrenia: extending the MFG test to include multiple siblings and birth order. 61
14735156 2004
225
[Significance of alloantibodies other than anti-D hemolytic disease of the fetus and newborn (HDF/N)]. 61
12715437 2003
226
Antibody-induced anemia in fetal sheep: model for hemolytic disease of the fetus and newborn. 61
11525898 2001
227
Use of Rh immune globulin: ASCP practice parameter. American Society of Clinical Pathologists. 61
9728602 1998
228
The management of hemolytic disease in the fetus and newborn. 61
9190032 1997
229
Prenatal testing to predict the severity of hemolytic disease of the fetus and newborn. 61
9372121 1996
230
Management of late anemia in Rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study). 61
8726237 1996
231
Rhesus incompatibility as a risk factor for schizophrenia in male adults. 61
8540773 1996
232
An animal model for hemolytic disease of the fetus and newborn. II. Fetal effects in New Zealand rabbits. 61
7573237 1995
233
An animal model for hemolytic disease of the fetus and newborn. I. Alloimmunization techniques. 61
7631726 1995
234
Monocyte monolayer assay as a predictor of severity of hemolytic disease of the fetus and newborn. 61
8267805 1993
235
Suppression of erythropoiesis by intrauterine transfusions in hemolytic disease of the newborn: use of erythropoietin to treat the late anemia. 61
8345428 1993
236
[Late results of using plasmapheresis. Prevention of hemolytic disease of the fetus and newborn infant in Rh-compromised pregnancy]. 61
3101532 1986
237
Efforts should be made to eradicate Rh hemolytic disease of the fetus and newborn. 61
6320075 1984
238
[The influence of the concentration and time of appearance of rhesus antibodies in the mother's blood on the frequency and severity of hemolytic disease of the fetus and newborn]. 61
5005615 1971
239
[Diagnostic value of spectrophotometric examination of the amniotic fluid in hemolytic disease of the fetus and newborn]. 61
5362458 1969
240
Hemolytic disease of the fetus and newborn. 61
5319487 1965
241
The management of hemolytic disease of the fetus and newborn infant. 61
15408726 1949

Variations for Hemolytic Disease Due to Fetomaternal Alloimmunization

ClinVar genetic disease variations for Hemolytic Disease Due to Fetomaternal Alloimmunization:

6 (showing 1, show less) ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SLC29A1 NM_001078177.2(SLC29A1):c.1159A>C (p.Thr387Pro)SNV Pathogenic 429191 rs1131690802 6:44200643-44200643 6:44232906-44232906

Expression for Hemolytic Disease Due to Fetomaternal Alloimmunization

Search GEO for disease gene expression data for Hemolytic Disease Due to Fetomaternal Alloimmunization.

Pathways for Hemolytic Disease Due to Fetomaternal Alloimmunization

GO Terms for Hemolytic Disease Due to Fetomaternal Alloimmunization

Sources for Hemolytic Disease Due to Fetomaternal Alloimmunization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....